Editorial
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2017; 23(38): 6923-6926
Published online Oct 14, 2017. doi: 10.3748/wjg.v23.i38.6923
Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer
Emilio De Raffele, Mariateresa Mirarchi, Dajana Cuicchi, Ferdinando Lecce, Bruno Cola
Emilio De Raffele, Dajana Cuicchi, Ferdinando Lecce, Bruno Cola, Unità Operativa di Chirurgia Generale, Dipartimento dell’Apparato Digerente, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy
Mariateresa Mirarchi, U.O. di Chirurgia Generale, Dipartimento Strutturale Chirurgico, Ospedale “SS Antonio e Margherita”, 15057 Tortona, Italy
Author contributions: De Raffele E conceived of and designed the study, and wrote the manuscript; De Raffele E, Mirarchi M, Cuicchi D and Lecce F contributed to acquisition, analysis and interpretation of data; Cola B made critical revisions on and provided final approval of the paper.
Conflict-of-interest statement: None of the authors have any conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Emilio De Raffele, MD, PhD, Unità Operativa di Chirurgia Generale, Dipartimento dell’Apparato Digerente, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy. e.deraffele@aosp.bo.it
Telephone: +39-51-6364235 Fax: +39-51-6363412
Received: July 4, 2017
Peer-review started: July 5, 2017
First decision: July 28, 2017
Revised: August 28, 2017
Accepted: September 19, 2017
Article in press: September 19, 2017
Published online: October 14, 2017
Core Tip

Core tip: Gastric cancer (GC) is still a leading cause of cancer death worldwide. Prognosis depends on surgical curability, response to adjuvant therapies, tumour stage and histology, but also on the systemic inflammatory response to malignancy. While the diagnostic role of positron emission tomography with 18F-fluorodeoxyglucose (FDG) in GC is still debated, due to unsatisfactory sensitivity, there is growing evidence that FDG uptake, either at the tumour sites or in the bone marrow, may represent an efficient tool for predicting prognosis of resected patients and for monitoring tumour response to adjuvant treatments, and may have prognostic value in directing therapeutic strategies.